查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587848

半固态CDMO 市场规模、份额和趋势分析报告：按管理途径、产品、服务、最终用途、国家和细分市场进行预测，2024-2030 年

Semi-Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Route of Administration (Topical, Transdermal, Others), By Product, By Service, By End Use, By Country, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10个工作天内

价格

半固态CDMO 市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球半固态CDMO市场将达到674亿美元，2024年至2030年复合年增长率为11.80%。

全球半固态CDMO 市场规模是由个人化医疗的成长趋势以及对创新药物输送系统不断增长的需求所推动的。乳膏、凝胶和软膏等固态製剂因其易于涂布和快速吸收而受到患者的青睐。此外，它在皮肤科治疗中广泛采用，以增加患者的治疗选择。根据美国皮肤病学会协会 2024 年 9 月发布的资料，痤疮是最常见的疾病，每年影响美国约 5,000 万人。而且，其中85%的人年龄在12岁至24岁之间。因此，皮肤病患病率的不断上升导致对外用製剂开发的需求增加，从而推动对 CDMO 扩大其半固态製剂能力的需求。

此外，製剂和製造流程的持续技术进步也推动了半固态药物市场的发展。奈米技术和先进乳化技术等创新正在提高固态製剂的功效和稳定性。这些进步使 CDMO 能够生产满足严格监管要求的高品质产品，从而吸引更多客户。例如，乳化的开发提高了活性成分的生物有效性，使固态製剂能够更有效地用于治疗慢性疼痛和发炎疾病等各种病症。

此外，慢性病盛行率的增加以及人口老化也促进了半固态CDMO 市场的成长。随着越来越多的人寻求关节炎、糖尿病和皮肤病等疾病的治疗，预计未来几年对有效半固态製剂的需求将会增加。这种趋势在老年医学中尤其明显，固态製剂因其易于使用而通常受到青睐。因此，这些因素进一步促进了市场的成长。

固态CDMO 市场报告亮点

  • 从产品来看，外用製剂将在2023年占据市场主导地位，份额为88.48%。这些製剂对于局部治疗特别有效，是皮肤科应用的理想选择。
  • 从给药途径来看，2023 年乳霜和乳液占据市场主导地位。这些配方具有独特的优点，例如易于涂布、质地宜人、改善皮肤吸收，有助于该细分市场的成长。
  • 按服务划分，契约製造製造业在 2023 年销售额中所占份额最大。为了专注于研发等核心能力，製药公司越来越多地将其製造流程委託给 CDMO。
  • 以最终用途划分，製药公司细分市场在 2023 年占据最大收益占有率。这是由于对创新治疗解决方案的需求增加导致公司增加了对开发新药的投资。
  • 2023年，北美市场占据主导地位，份额为41.12%。该地区慢性病患病率的上升以及对先进治疗解决方案的需求不断增加正在推动市场扩张。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章半固态CDMO市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 半固态CDMO市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章半固态CDMO市场：给药途径预估及趋势分析

  • 按管理途径分類的半固态CDMO 市场：细分仪表板
  • 半固态CDMO 市场，依管理途径：变化分析
  • 依途径，2018-2030
    • 外用
    • 经皮的
    • 其他的

第五章 半固态CDMO市场：产品预估及趋势分析

  • 半固态CDMO 市场，副产品：细分仪表板
  • 半固态CDMO市场，依产品：变化分析
  • 按产品划分，2018-2030
    • 软膏
    • 霜和乳液
    • 贴上
    • 凝胶
    • 其他的

第六章 半固态CDMO市场：服务评估与趋势分析

  • 半固态CDMO 市场，依服务分类：细分仪表板
  • 半固态CDMO市场，按服务：波动分析
  • 按服务划分，2018-2030
    • 合约开发
    • 契约製造

第七章 半固态CDMO市场：最终用途估算与趋势分析

  • 半固态CDMO 市场，依最终用途：细分仪表板
  • 半固态CDMO 市场，依最终用途：变化分析
  • 按最终用途划分，2018-2030
    • 製药公司
    • 生物製药公司
    • 其他的

第八章 半固态CDMO市场：区域估算及趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场简介
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 丹麦
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 泰国
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 市场参与企业分类
    • 创新者
    • 市场领导者
    • 新兴玩家
  • 2023 年公司市场占有率/地位分析
  • 公司简介
    • The Lubrizol Corporation
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited.
    • Bora Pharmaceutical
    • Ascendia Pharmaceuticals
    • Pierre Fabre group
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD
    • LGM Pharma
    • Pace Analytical Life Sciences, LLC.
Product Code: GVR-4-68040-477-4

Semi-Solid Dosage CDMO Market Growth & Trends:

The global semi-solid Dosage CDMO market is expected to reach USD 67.4 billion by 2030, and anticipated to grow at a CAGR of 11.80% from 2024 to 2030 according to a new report by Grand View Research, Inc. The global semi-solid dosage CDMO market size is driven due to growing trend towards personalized medicine coupled with increasing demand for innovative drug delivery systems. Patients prefer semi-solid formulations, such as creams, gels, and ointments, due to their ease of application and rapid absorption. Moreover, it has significant adoption for dermatological treatments to enhance patient treatment options. According to the data published by the American Academy of Dermatology Association in September 2024, Acne is the most common condition affecting approximately 50 million people in the U.S. annually. Moreover, 85% of the people are among age 12 to 24. Thus, increasing prevalence of skin disorders has led to an increasing demand for the development of topical formulations, consequently driving the demand for CDMOs to expand their capabilities in semi-solid dosage forms.

Furthermore, constant technological advancements in formulation and manufacturing processes have also propelled the semi-solid dosage market. Innovations such as nanotechnology and advanced emulsion techniques have improved the efficacy and stability of semi-solid formulations. These advancements enable CDMOs to produce high-quality products that meet stringent regulatory requirements, thereby attracting more clients. For instance, the development of nano-emulsions has enhanced the bioavailability of active ingredients, making semi-solid formulations more effective in treating various conditions, including chronic pain and inflammatory diseases.

In addition, increasing prevalence of chronic diseases, coupled with an aging population, is also contributing to the growth of the semi-solid dosage CDMO market. As more individuals seek treatments for conditions such as arthritis, diabetes, and skin disorders, the demand for effective semi-solid formulations is projected to increase in the coming years. This trend is particularly prominent in geriatric care, where semi-solid forms are often preferred due to their ease of use. Thus, these factors are further contributing to the market growth.

Semi-Solid Dosage CDMO Market Report Highlights:

  • Based on product, topical segment dominated in the market with a share of 88.48% in 2023. These formulations are particularly effective for localized treatments, making them ideal for dermatological applications
  • Based on rout of administration, creams and lotions dominated the market in 2023. These formulations offer unique benefits such as ease of application, pleasant texture, and enhanced skin absorption which is contributing to the segment's growth
  • Based on service, the contract manufacturing segment accounted for the largest revenue share in 2023. Pharmaceutical companies are increasingly outsourcing their manufacturing processes to CDMOs to focus on core competencies such as research and development
  • Based on end use, the pharmaceutical companies segment accounted for the largest revenue share in 2023 owing to the increasing demand for innovative therapeutic solutions which has resulted into the increasing investment by the companies for the development of new drugs
  • North America dominated the market with a share of 41.12% in 2023. The increasing prevalence of chronic diseases and increasing demand for advanced therapeutic solutions in the region are propelling market expansion

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Route of Administration
    • 1.2.2. Product
    • 1.2.3. Service
    • 1.2.4. End Use
  • 1.3. Regional Scope
  • 1.4. Estimates And Forecast Timeline
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Semi-Solid Dosage CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Semi-Solid Dosage CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Semi-Solid Dosage CDMO Market: Route of Administration Estimates & Trend Analysis

  • 4.1. Semi-Solid Dosage CDMO Market, By Route of Administration: Segment Dashboard
  • 4.2. Semi-Solid Dosage CDMO Market, By Route of Administration: Movement Analysis
  • 4.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Route of Administration, 2018 - 2030
    • 4.3.1. Topical
      • 4.3.1.1. Topical Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.2. Transdermal
      • 4.3.2.1. Transdermal Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.3. Others
      • 4.3.3.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Semi-Solid Dosage CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Semi-Solid Dosage CDMO Market, By Product: Segment Dashboard
  • 5.2. Semi-Solid Dosage CDMO Market, By Product: Movement Analysis
  • 5.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
    • 5.3.1. Ointments
      • 5.3.1.1. Ointments Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2. Creams and Lotions
      • 5.3.2.1. Creams and Lotions Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.3. Pastes
      • 5.3.3.1. Pastes Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.4. Gels
      • 5.3.4.1. Gels Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.5. Others
      • 5.3.5.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Semi-Solid Dosage CDMO Market: Service Estimates & Trend Analysis

  • 6.1. Semi-Solid Dosage CDMO Market, By Service: Segment Dashboard
  • 6.2. Semi-Solid Dosage CDMO Market, By Service: Movement Analysis
  • 6.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By Service, 2018 - 2030
    • 6.3.1. Contract Development
      • 6.3.1.1. Contract Development Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 6.3.2. Contract Manufacturing
      • 6.3.2.1. Contract Manufacturing Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 7. Semi-Solid Dosage CDMO Market: End Use Estimates & Trend Analysis

  • 7.1. Semi-Solid Dosage CDMO Market, By End Use: Segment Dashboard
  • 7.2. Semi-Solid Dosage CDMO Market, By End Use: Movement Analysis
  • 7.3. Semi-Solid Dosage CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
    • 7.3.1. Pharmaceutical Companies
      • 7.3.1.1. Pharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 7.3.2. Biopharmaceutical Companies
      • 7.3.2.1. Biopharmaceutical Companies Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)
    • 7.3.3. Others
      • 7.3.3.1. Others Semi-Solid Dosage CDMO Market, 2018 to 2030 (USD Million)

Chapter 8. Semi-Solid Dosage CDMO Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2023 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. North America
    • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.5. Europe
    • 8.5.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.7. Sweden
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Sweden Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Denmark Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.6. Asia Pacific
    • 8.6.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.5. Thailand
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Thailand Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.6.7. Australia
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Australia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.7. Latin America
    • 8.7.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
  • 8.8. MEA
    • 8.8.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Semi-Solid Dosage CDMO Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
    • 9.1.1. Innovators
    • 9.1.2. Market Leaders
    • 9.1.3. Emerging Players
  • 9.2. Company Market Share/Position Analysis, 2023
  • 9.3. Company Profiles
    • 9.3.1. The Lubrizol Corporation
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Service Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Cambrex Corporation
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Service Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Contract Pharmaceuticals Limited.
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Service Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Bora Pharmaceutical
      • 9.3.4.1. Company Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Service Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Ascendia Pharmaceuticals
      • 9.3.5.1. Company Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Service Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Pierre Fabre group
      • 9.3.6.1. Company Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Service Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Piramal Pharma Solutions
      • 9.3.7.1. Company Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Service Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. DPT Laboratories, LTD
      • 9.3.8.1. Company Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Service Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. LGM Pharma
      • 9.3.9.1. Company Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Service Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Pace Analytical Life Sciences, LLC.
      • 9.3.10.1. Company Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Service Benchmarking
      • 9.3.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of Tables
  • Table 2. List of Secondary Sources
  • Table 3. List of Abbreviations
  • Table 4. Global Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 5. Global Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 6. Global Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 7. Global Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 8. Global Semi-Solid Dosage CDMO, by Region, 2018 - 2030 (USD Million)
  • Table 9. North America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 10. North America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 11. North America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 12. North America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 13. North America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 14. U.S. Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15. U.S. Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 16. U.S. Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 17. U.S. Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 18. Canada Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19. Canada Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 20. Canada Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 21. Canada Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 22. Mexico Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 23. Mexico Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 24. Mexico Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 25. Mexico Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 26. Europe Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 27. Europe Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28. Europe Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 29. Europe Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 30. Europe Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 31. UK Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 32. UK Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 33. UK Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 34. UK Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 35. Germany Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 36. Germany Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 37. Germany Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 38. Germany Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 39. France Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40. France Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 41. France Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 42. France Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 43. Italy Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 44. Italy Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 45. Italy Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 46. Italy Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 47. Spain Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 48. Spain Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 49. Spain Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 50. Spain Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 51. Denmark Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52. Denmark Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 53. Denmark Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 54. Denmark Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 55. Sweden Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56. Sweden Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 57. Sweden Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 58. Sweden Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 59. Norway Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 60. Norway Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 61. Norway Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 62. Norway Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 67. Asia Pacific Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 68. Japan Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 69. Japan Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 70. Japan Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 71. Japan Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 72. China Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 73. China Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 74. China Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 75. China Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 76. India Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 77. India Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 78. India Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 79. India Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 80. Thailand Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 81. Thailand Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 82. Thailand Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 83. Thailand Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 84. South Korea Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 85. South Korea Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 86. South Korea Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 87. South Korea Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 88. Australia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 89. Australia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 90. Australia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 91. Australia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 92. Latin America Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 93. Latin America Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94. Latin America Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 95. Latin America Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 96. Latin America Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 97. Brazil Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 98. Brazil Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 99. Brazil Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 100. Brazil Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 101. Argentina Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 102. Argentina Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 103. Argentina Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 104. Argentina Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa Semi-Solid Dosage CDMO, by Country, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 109. Middle East & Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 110. South Africa Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 111. South Africa Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 112. South Africa Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 113. South Africa Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 117. Saudi Arabia Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 118. UAE Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 119. UAE Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 120. UAE Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 121. UAE Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)
  • Table 122. Kuwait Semi-Solid Dosage CDMO, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 123. Kuwait Semi-Solid Dosage CDMO, by Product, 2018 - 2030 (USD Million)
  • Table 124. Kuwait Semi-Solid Dosage CDMO, by Service, 2018 - 2030 (USD Million)
  • Table 125. Kuwait Semi-Solid Dosage CDMO, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Semi-Solid Dosage CDMO Market revenue, 2018-2030 (USD Million)
  • Fig. 10 Semi-Solid Dosage CDMO Market snapshot
  • Fig. 11 Semi-Solid Dosage CDMO Market driver impact
  • Fig. 12 Semi-Solid Dosage CDMO Market restraint impact
  • Fig. 13 Semi-Solid Dosage CDMO sector Route of administration takeaways (USD Million)
  • Fig. 14 Semi-Solid Dosage CDMO Market: Route of administration movement analysis
  • Fig. 15 Topical market, 2018 - 2030 (USD Million)
  • Fig. 16 Transdermal market, 2018 - 2030 (USD Million)
  • Fig. 17 Others market, 2018 - 2030 (USD Million)
  • Fig. 18 Semi-Solid Dosage CDMO sector Product takeaways (USD Million)
  • Fig. 19 Semi-Solid Dosage CDMO Market: Product movement analysis
  • Fig. 20 Ointments market, 2018 - 2030 (USD Million)
  • Fig. 21 Creams and Lotions market, 2018 - 2030 (USD Million)
  • Fig. 22 Pastes market, 2018 - 2030 (USD Million)
  • Fig. 23 Gels market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Semi-Solid Dosage CDMO sector Service takeaways (USD Million)
  • Fig. 26 Semi-Solid Dosage CDMO Market: Service movement analysis
  • Fig. 27 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 28 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 29 Semi-Solid Dosage CDMO sector End Use takeaways (USD Million)
  • Fig. 30 Semi-Solid Dosage CDMO Market: End Use movement analysis
  • Fig. 31 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 32 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
  • Fig. 33 Others market, 2018 - 2030 (USD Million)
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional outlook, 2023 & 2030
  • Fig. 36 North America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 38 Canada Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 41 UK Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 42 Germany Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 43 France Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 45 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 47 Denmark Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 48 Norway Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 49 Asia Pacific Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 50 Japan Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 51 China Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 52 India Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 54 South Korea Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 55 Australia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 56 Latin America Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 57 Brazil Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 58 Argentina Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 59 Middle East & Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 61 Saudi Arabia Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 62 UAE Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 63 Kuwait Semi-Solid Dosage CDMO Market, 2018 - 2030 (USD Million)
  • Fig. 64 Market participant categorization